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Abstract
Introduction Keratin 6 (K6) has previously been identified as a
marker of early mammary gland development and has also been
proposed to be a marker of mammary gland progenitor cells.
However, the function of K6 in the mammary gland was not
known, so we examined the expression pattern of the protein
during both embryonic and postnatal mammary development, as
well as the mammary gland phenotype of mice that were null for
both K6a and K6b isoforms.
Method Immunostaining was performed to determine the
expression pattern of K6a throughout mammary gland
development, from the embryonic mammary bud to lactation.
Double immunofluorescence was used to co-localize K6 with
known markers of mammary gland development. Wild-type and
K6ab-null mammary tissues were transplanted into the cleared
fat pads of nude mice and the outgrowths were analyzed for
morphology by whole-mount staining and for markers of
mammary epithelium by immunostaining. Finally, progesterone
receptor (PR) and bromodeoxyuridine co-localization was
quantified by double immunofluorescence in wild-type and
K6ab-null mammary outgrowths.
Results Here we report that K6 is expressed earlier than
described previously, by embryonic day 16.5. K6a is the
predominant isoform expressed in the mammary gland, localized
in the body cells and luminal epithelial cells but not in the cap
cells or myoepithelial cells. Co-localization studies showed that
most K6a-positive cells express steroid receptors but do not
proliferate. When both the K6a and K6b genes are deleted,
mammary gland development appears normal, with similar
expression of most molecular markers examined in both the
pubertal gland and the mature gland. Loss of K6a and K6b,
however, leads to an increase in the number of steroid-receptor-
positive cells, and increased co-localization of steroid receptor
expression and proliferation was observed.
Conclusion Although K6a was not essential for mammary gland
development, loss of both K6a and K6b resulted in an increase
in PR-positive mammary epithelial cells and decreased
proliferation after exposure to steroid hormones. There was also
increased co-localization of PR and bromodeoxyuridine,
suggesting alterations in patterning events important for normal
lobuloalveolar development.
Introduction
The mammary gland is unique in that its development primarily
occurs postnatally. However, the tissue is initially formed dur-
ing embryonic development (reviewed in [1]). A milk line first
appears at about embryonic day 10.5 (E10.5). At E11.5, five
pairs of placodes have formed at specific positions along the
milk line, and by E12.5 mammary buds invaginate from the
ectoderm, surrounded by a specialized mammary mesen-
chyme. These mammary anlagen begin to form a lumen by
E16.5 and sprout into the underlying fat pad. Branching mor-
phogenesis then occurs, to give rise to a rudimentary ductal
tree in the newborn pups.
Any piece of the mammary gland, from the embryonic mam-
mary bud to the differentiated gland, can be transplanted into
a cleared fat pat to generate another ductal structure contain-
ing all the epithelial cell types that make up the mammary
gland, supporting the idea that progenitor cells are dispersed
throughout the tissue [2]. Although lineage markers have been
identified in the hematopoietic system and epidermis, a clear
picture of mammary lineage markers is still evolving [3-5].
BrdU = bromodeoxyuridine; C/EBP = CCAAT-enhancer binding protein; E = embryonic day; E + P = estrogen and progesterone; ERα = estrogen 
receptor α; K5 = keratin 5; K6 = keratin 6; K8 = keratin 8; MEC = mammary epithelial cell; PR = progesterone receptor; SMA = smooth muscle α-
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However, a handful of putative markers have been identified,
including keratin 6 (K6) [6,7].
Cytokeratins, members of the intermediate filament super-
family, are the main structural components of most epithelial
cells. There are more than 55 keratins, consisting of type I (K9
to K20) and type II (K1 to K8) filaments that partner to form
coiled-coil heterodimers [8]. Although multiple genes encod-
ing K6 isoforms exist in both human and mouse, the mouse
genes seem to have evolved after the species diverged [9].
The mouse isoforms, K6a and K6b, are organized in tandem
on chromosome 15 and although their coding sequences
show 95% identity, the two genes are differentially regulated
at the transcriptional level [10-12]. Germline deletion of both
K6a and K6b genes led to the discovery of a third murine iso-
form, K6hf, expressed mainly in hair follicles [12]. Expression
of K6 in the skin is associated with hyperproliferative disorders
and in response to stressful stimuli, such as wounding [13].
After an injury, K6 is expressed at the wound site, where its
expression is associated with activated keratinocytes [14].
However, the function of K6 in mammary gland development
is not known.
K6 is expressed in terminal end buds (TEBs) of the developing
mammary gland [15,16]. Ductal elongation is a highly prolifer-
ative phase of mammary gland development, but K6 expres-
sion is restricted to the body cells of the TEB and not the
proliferative cap cell layer surrounding the tip of the TEB. How-
ever, expression of K6 is rare in the mature mammary gland
[7,16]. Additionally, K6 is misexpressed in mature mammary
glands from mice that were null for CCAAT-enhancer binding
protein-β (C/EBPβ), coinciding with an arrested state of differ-
entiation and a block in cell fate [6].
The function of K6 in the mammary gland is not known, so we
examined the expression pattern throughout mammary devel-
opment, as well as the mammary gland phenotype of mice that
are null for both K6a and K6b isoforms (K6ab-null). Here we
report that K6 is expressed earlier than described previously,
by E16.5. K6a is the predominant isoform expressed in the
mammary gland, localized in the body cells and luminal epithe-
lial cells but not in the cap cells or myoepithelial cells. Co-local-
ization studies showed that most K6a-positive cells express
steroid receptors but do not proliferate. When both the K6a
and K6b genes are deleted, mammary gland development
appears normal, with similar expression of most molecular
markers examined in both the pubertal gland and the mature
gland. However, an increase in the number of steroid-recep-
tor-positive cells and increased co-localization of steroid
receptor expression with proliferation were observed.
Materials and methods
Animals and tissue isolation
Animal care and procedures were approved by the Institutional
Animal Care and Use Committee of Baylor College of Medi-
cine and were in accordance with the procedures detailed in
the Guide for Care and Use of Laboratory Animals (NIH publi-
cation 85–23). Mice with targeted germline deletion of K6a
and K6b have been described previously [12]. Mammary
glands were removed from intact 6-week-old wild-type (WT)
and K6ab-null mice after an intraperitoneal injection with 5-
bromo-2'-deoxyuridine (BrdU; 0.03 mg/g body weight; Sigma,
St Louis, MO, USA) 2 hours before being killed. Mammary
glands were also isolated from C57Bl/6 mice at various
stages of development (embryonic days 14 and 16.5, day 5
pups, 6 and 12 weeks, days 10, 15, 18 of pregnancy, days 2
and 9 of lactation and day 3 of involution). After fixation for 2
hours in cold 4% paraformaldehyde, the tissues were embed-
ded in paraffin. Mammary glands and skin samples were addi-
tionally collected from 6-week-old FVB females that were
injected intraperitoneally with BrdU 2 hours before being
killed. These tissues were either fixed overnight in 10% nor-
mal-buffered formalin (NBF) and embedded in paraffin or fro-
zen in OCT (Optimal Cutting Temperature) for cryosectioning.
Paraffin-embedded mammary glands and skin samples were
sectioned (5 to 7 µm) onto Probe-On Plus charged slides
(Fisher Scientific, Pittsburgh, PA, USA). Frozen sections were
cut at 5 µm thickness and fixed in acetone for 10 minutes.
Mammary gland transplants
Mammary gland tissues from adult WT or K6ab-null mice were
cut into small pieces (about 1 mm3) that were inserted into the
cleared fat pads of 3-week-old athymic nu/nu mice [17]. All
clearings were subjected to whole-mount staining to verify that
all epithelium was removed from the fat pad. Primary trans-
plants were allowed to grow out for at least 16 weeks so that
the fat pad was completely filled with epithelium. These out-
growths were removed, cut into small pieces, and slowly fro-
zen in RPMI-1640 medium containing 2% fetal bovine serum
with 7% dimethylsulphoxide and used to perform secondary
transplants. Outgrowths were taken at 4 and 10 weeks after
transplantation. At 10 weeks after transplantation, the host
mice were treated for 48 hours with a single interscapular sub-
cutaneous injection of 17β-estradiol benzoate (1 µg) and pro-
gesterone (1 mg) in 100 µl of sesame oil (all from Sigma). At
2 hours before being killed, animals were injected with BrdU.
After fixation for 2 hours in cold 4% paraformaldehyde, the
glands were cut in half lengthways. One half was embedded
in paraffin and the other was subjected to hematoxylin whole-
mount staining. Whole-mount images were captured with an
Olympus SZ40 dissecting microscope connected to a QCap-
ture digital camera.
Antibodies and immunostaining
Paraffin-embedded tissue sections were deparaffinized in
xylene, then rehydrated through a graded ethanol series.
Immunostaining was performed after microwave antigen
retrieval (20 minutes) in 10 mM sodium citrate and blocking in
5% bovine serum albumin in phosphate-buffered saline con-
taining 0.5% Tween 20. For immunohistochemistry, sectionsAvailable online http://breast-cancer-research.com/content/8/3/R29
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were incubated overnight with the following primary antibod-
ies at room temperature: K6 rabbit polyclonal at a dilution of
1:5000 (Covance, Richmond, CA, USA), keratin 5 (K5) rabbit
polyclonal at 1:5000 (Covance), keratin 8 (K8) rat monoclonal
at 1:5000 (University of Iowa Developmental Studies Hybrid-
oma Bank), estrogen receptor α (ERα) rabbit polyclonal at
1:5000 (Santa Cruz Biotechnology, Santa Cruz, CA, USA),
and biotinylated BrdU mouse monoclonal at 1:50 (BD Bio-
sciences, San Jose, CA, USA). Immunoperoxidase staining
was detected using the appropriate biotinylated secondary
antibodies and Vectastain Elite ABC and diaminobenzidine
substrate kits in accordance with manufacturer's instructions
(Vector Laboratories, Burlingame, CA, USA). For immunofluo-
rescence, sections were incubated overnight with the follow-
ing primary antibodies at room temperature: K6a rabbit
polyclonal at 1:100 (Covance), K6b/hf guinea pig polyclonal
at 1:100 [11], smooth muscle α-actin (SMA) mouse mono-
clonal at 1:100 (Dako, Carpinteria, CA, USA), K8 rat mono-
clonal at 1:100 (University of Iowa Developmental Studies
Hybridoma Bank), ERα rabbit polyclonal at 1:1000 (Santa
Cruz Biotechnology), fluorescein isothiocyanate-conjugated
BrdU at 1:10 (BD Biosciences), and progesterone receptor
(PR) rabbit polyclonal at 1:50 (Dako). Immunofluorescence
staining was detected with the appropriate secondary anti-
bodies conjugated with Texas Red, Alexa 568, or Alexa 488
(Molecular Probes, Eugene, OR, USA), and nuclei were coun-
terstained with 4', 6-diamidino-2-phenylindole (DAPI; Vector
Laboratories).
Image capture, cell counting and statistical analysis
An Olympus BX40 light microscope connected to a Mag-
naFire digital camera was used to capture images from immu-
nohistochemical staining. A Zeiss Axioskop2 Plus
fluorescence microscope connected to an AxioCamMR digital
camera was used to capture images from immunofluores-
cence staining with Axiovision Rel. 4.2 software. At least eight
individual 40× fields per group were captured for counting.
K6a-positive cells were scored and then the number of cells
expressing ERα or BrdU in that subset was counted. Fluores-
cent images of PR and BrdU immunostaining were captured
digitally with an Olympus BX50 microscope connected to a
Hamamatsu C5810 charge-coupled device camera. At least
eight individual 60× fields per sample were captured for
counting. The number of positively stained mammary epithelial
cell (MEC) nuclei was expressed as a percentage of the total
number of luminal epithelial cells. Statistical significance was
determined by Student's t test (two-sample assuming unequal
variance).
Results
Three isoforms of mouse K6 exist, namely K6a, K6b and K6hf
[12]. To determine which isoforms are expressed in the mam-
mary gland, immunostaining was performed on tissue sections
with the use of antibodies that specifically recognize either K6
or K6b/hf (Figure 1). An embryonic mammary bud from E16.5
stained positively for K6a (Figure 1a) but an adjacent section
showed no immunoreactivity with the K6b/hf antibody (Figure
1b). Indirect immunofluorescence revealed K6a-positive body
cells in a TEB from a 6-week mammary gland (Figure 1c), but
no K6b/hf staining was detected (Figure 1d). A positive con-
trol is shown in Figure 1e,f, in which both antibodies stained
the outer root sheath of a hair follicle from a 6-week skin sam-
ple. K6a is therefore the predominant isoform expressed in the
mouse mammary gland.
K6 expression has been reported previously in the body cells
of TEBs from pubertal mice [15,16], but its expression earlier
in mammary gland development has not been reported. Paraf-
fin-embedded tissue sections from various stages of develop-
ment were stained by immunohistochemistry with the use of an
anti-K6a antibody (Figure 2). At embryonic day 14, expression
of K6a was not observed in the mammary bud (Figure 2a),
although positive staining was detected in other regions of the
embryo (data not shown). By E16.5 (Figure 2b), when the
Figure 1
Keratin 6a (K6a) is the predominant isoform expressed in the mammary  gland Keratin 6a (K6a) is the predominant isoform expressed in the mammary 
gland. Antibodies that recognize either the K6a or K6b/hf isoform were 
used to immunostain sections from either E16.5 embryonic mammary 
buds (a,b), terminal end buds (TEBs) from 6-week FVB mouse mam-
mary glands (c,d) or hair follicles (e,f). K6a stained the mammary bud 
and body cells of the TEB as well as the hair follicle, but Kb6/hf was 
detected only in the hair follicle. Scale bar, 50 µm.Breast Cancer Research    Vol 8 No 3    Grimm et al.
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center of the mammary bud begins to keratinize in preparation
for formation of the lumen and branching, K6a expression was
observed in the center of the bud but not in the outermost ring
of epithelial cells and not in the mammary mesenchyme. Five
days after birth, K6a expression was seen in most of the lumi-
nal epithelial cells making up the rudimentary ductal tree (Fig-
ure 2c). By six weeks of age, when TEB structures are
infiltrating the fat pad, many of the body cells in the TEBs were
positive for K6a, whereas the highly proliferative cap cell layer
at the tip of the TEB did not express K6a (Figure 2d,e). Nota-
Figure 2
Keratin 6a (K6a) expression during mammary gland development Keratin 6a (K6a) expression during mammary gland development. Tissues isolated from C57Bl/6 mice during various stages of mammary gland 
development were stained by immunohistochemistry with an antibody to detect K6a expression. (a) Embryonic day 14 mammary bud, (b) embryonic 
day 16.5 mammary bud, (c) day 5 pup, (d,e) 6-week terminal end bud, (f) 6-week pubertal duct, (g) 12-week mature duct treated for 2 days with 
estrogen and progesterone, (h) mature duct after treatment for 21 days with estrogen and progesterone, (i) day 10 pregnancy, (j) day 15 preg-
nancy, (k) day 18 pregnancy, (l) lactation day 2, (m) lactation day 9, (n) involution day 3, (o) 12-week mature duct from CCAAT-enhancer-binding 
protein-β-null mammary gland, (p) 12-week mature duct from K6ab-null mammary gland. Scale bar, 100 µm.Available online http://breast-cancer-research.com/content/8/3/R29
Page 5 of 11
(page number not for citation purposes)
bly, some of the body cells showed more intense staining than
others. The luminal epithelial cells in ducts from 6-week puber-
tal mice strongly expressed K6a (Figure 2f), but expression
was markedly downregulated by 12 weeks in a mature gland
(Figure 2g). K6 expression is associated with activated kerati-
nocytes in the skin, a state of hyperproliferation [13], but after
chronic (21 days) hormone treatment with estrogen and pro-
gesterone (E + P) to induce proliferation in the mammary
gland, K6a expression remained sporadic (Figure 2h). The
same was true throughout pregnancy at days 10, 15, and 18
(Figure 2i–k), lactation at days 2 and 9 (Figure 2l,m), and at
day 3 of involution (Figure 2n). Very few K6a-positive cells
could be found in sections from these stages of development
(indicated by arrows). Mammary glands from C/EBPβ-null and
K6ab-null mice served as positive and negative controls for
K6a staining, respectively (Figure 2o,p). These patterns of
expression are consistent with what is expected of a progeni-
tor cell marker.
Figure 3
Co-localization of keratin 6a (K6a) expression with markers of mammary epithelium Co-localization of keratin 6a (K6a) expression with markers of mammary epithelium. Indirect immunofluorescence was performed on mammary gland 
sections from 6-week FVB mice, containing both terminal end buds (left column) and ducts (right column). K6a staining is shown in green for all sec-
tions. Co-localization was performed for smooth muscle α-actin (a,b), K8 (c,d), estrogen receptor α (e,f), and bromodeoxyuridine (h,i), which are all 
shown in red. Quantification of K6a-positive cells co-expressing estrogen receptor α or bromodeoxyuridine is shown in the bar graphs (g,j). Scale 
bar, 50 µm.Breast Cancer Research    Vol 8 No 3    Grimm et al.
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To gain insight into the function of K6 during mammary gland
development, double immunofluorescence staining was per-
formed to co-localize K6a expression with known markers of
mammary epithelium (Figure 3). Representative staining is
shown from TEBs (left panels) or 6-week ducts (right panels).
SMA was expressed in the cap cells of the TEB and in myoep-
ithelial cells surrounding the ducts of the mammary gland (red;
Figure 3a,b). However, K6a expression (green) was confined
to the body cells of the TEBs and the luminal epithelial cells of
ducts, and did not overlap with SMA expression (Figure 3a,b).
K8 and ERα are markers of luminal MECs. Double staining for
K6a with these proteins (Figure 3c–f) revealed nearly com-
plete co-localization, with yellow fluorescence showing over-
lapping staining for K6a (green) with K8 (red; Figure 3c,d).
More than 90% of the K6a-positive cells (green) expressed
ERα (red; Figure 3e–g). Staining was also performed for K6a
and BrdU, a marker of cells in S phase, to determine whether
K6a was expressed in proliferating cells (Figure 3h,i). Only
2.6% of K6a-positive cells (green) incorporated BrdU (red).
The K6a-positive cells that did co-localize with BrdU were
those that expressed lower levels of K6a; the strongly K6a-
positive cells were BrdU-negative.
To determine a functional role for K6 in mammary gland devel-
opment, the mammary glands from K6ab-null mice were ana-
lyzed. Double knockout mice, rather than K6a-null mice, were
used to avoid potential compensation by K6b after deletion of
K6a. Many K6ab-null mice die shortly after birth; a plaque of
cellular debris on the back of the tongue, due to disintegration
of the oral mucosa, prevents the pups from receiving proper
nourishment [12,18]. However, about 25% of the null mice
from the 129/SvEv background survive to adulthood [12].
Therefore, in addition to analyzing mammary glands from intact
animals, tissues from WT and null mice were also transplanted
Figure 4
Keratin 6ab (K6ab)-null mammary gland whole-mount analysis Keratin 6ab (K6ab)-null mammary gland whole-mount analysis. Mammary glands were isolated from intact wild-type (WT) or K6ab-null animals at 6 
weeks (a–d) or transplanted WT or K6ab-null tissues were harvested after either 4 weeks of outgrowth (e–h) or 10 weeks of outgrowth after 2 days 
of treatment with estrogen and progesterone (i–l). Whole-mount staining of the glands to reveal ductal structures is shown at two magnifications. 
Scale bar, 1 mm. LN, lymph node.Available online http://breast-cancer-research.com/content/8/3/R29
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and analyzed to rule out systemic effects on mammary gland
development. Whole-mount staining of glands from intact 6-
week animals (Figure 4a–d) revealed normal ductal develop-
ment in WT and K6ab-null glands; the TEBs had reached the
lymph node in both genotypes and the structures looked mor-
phologically similar. WT and K6ab-null mammary tissues were
transplanted into the cleared fat pads of host mice and
allowed to grow for four weeks. Outgrowths from these trans-
plants (Figure 4e–h) also displayed similar phenotypes and
morphology, suggesting that neither K6a nor K6b is essential
for ductal elongation in mammary gland development. Trans-
planted tissues were also allowed to grow out for ten weeks to
fill the fat pad fully. Acute hormone treatment with E + P for
two days was given to induce proliferation of mammary epithe-
lial cells. Outgrowths from both WT and mutant tissues were
indistinguishable, and both responded to the hormone treat-
ment as shown by alveolar budding along the ducts (Figure
4i–l).
Next, immunostaining for markers of mammary epithelium was
performed on sections from the WT and K6ab-null glands to
discern any molecular differences that might exist between the
two genotypes. Representative images from 6-week intact
glands, both TEBs and immature ducts, and from 10-week
outgrowths treated for 2 days with E + P, are shown in Figure
5. K5 is a marker of myoepithelial cells, and positive staining is
observed surrounding the TEBs, in the cap cell layer and
myoepithelial cells, as well as a few cells that infiltrated into the
body cells (Figure 5a,b). K5 staining showed a uniform pattern
in myoepithelial cells surrounding the immature ducts (Figure
5c,d) and more punctate staining around mature ducts (Figure
5e,f). Antibodies against K8 and ERα stained most of the body
cells in TEBs from WT and K6ab-null glands, but these pro-
teins were not expressed in the cap cells (Figure 5g,h,m,n).
Most of the luminal epithelial cells in ducts from 6-week ani-
mals uniformly expressed K8 and ERα (Figure 5i,j,o,p), but this
expression was downregulated and became non-uniform in
the mature gland (Figure 5k,l,q,r). Finally, immunostaining for
BrdU incorporation was performed to detect cells in S phase.
Both the body and cap cells in TEBs were highly proliferative
(Figure 5s,t). Few BrdU-positive cells were detected in the 6-
week ducts (Figure 5u,v), but higher levels of BrdU incorpora-
Figure 5
Marker expression in keratin 6ab (K6ab)-null mammary glands Marker expression in keratin 6ab (K6ab)-null mammary glands. Mammary gland sections from 6-week intact animals, including terminal end buds (left 
column) and ducts (middle column), or from transplanted tissue after 10 weeks of outgrowth and treatment for 2 days with estrogen and progester-
one (right column), were stained by immunohistochemistry for markers of mammary epithelium, including K5 (a–f), K8 (g–l), estrogen receptor α 
(m–r), and bromodeoxyuridine (s–x). Scale bar, 50 µm.Breast Cancer Research    Vol 8 No 3    Grimm et al.
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tion were observed in mature ducts after hormone treatment
(Figure 5w,x). In all cases, the WT and K6ab-null samples
showed similar staining patterns, suggesting that there were
no obvious molecular changes in the K6ab-null glands.
One of the hallmarks of normal mammary gland development
and patterning is the dissociation of steroid receptor expres-
sion from proliferating cells in the mature gland [19-21]. ERα
and PR co-localize, but cells expressing steroid receptors are
rarely BrdU-positive. Because most K6a-positive cells
expressed steroid receptors and were not proliferating, we
wanted to see what happened to PR and BrdU expression
after loss of K6ab. WT and K6ab-null mammary tissues were
transplanted and allowed to grow out for 10 weeks, then
treated for 2 days with E + P to induce proliferation. By whole-
mount analysis, it appeared that the K6ab-null transplants
responded to hormone treatment as well as WT, indicated by
the alveolar budding observed (Figure 4c,d). Indirect immun-
ofluorescence was used to stain sections for both PR (red)
and BrdU (green) and the percentages of MECs positive for
PR, BrdU or both were quantified (Figure 6a–c). The K6ab-null
transplants had a higher percentage of PR-positive MECs (p
< 0.05), and lower levels of proliferation than WT transplants
(p < 0.05). Whereas PR/BrdU co-localization was rare in WT
glands (0.6%), there was a threefold higher occurrence of
double-positive cells in K6ab-null glands (1.8%). Not only did
a higher percentage of MECs co-express PR and BrdU, more
of the fields counted contained the double-positive cells (22%
for WT versus 56% for null). So, although loss of K6ab does
not seem to significantly alter mammary gland development,
including ductal elongation and response to pregnancy hor-
mones, increased co-localization of steroid receptor expres-
sion and proliferation was observed.
Discussion
This study shows that the expression of K6 is highest during
the initial development of the gland and becomes sporadic in
the mature gland. K6a expression was confined to cells des-
tined to become the luminal epithelial cells of the mammary
gland. Even as early as E16.5, K6a expression was detected
in the innermost cells of the mammary bud, as opposed to the
outer ring of epithelial cells that are p63-positive (SLG and
JMR, unpublished observation). Similarly, the body cells of
TEBs, as opposed to the cap cell layer, expressed K6a. K6
expression in the epidermis has previously been shown to be
regulated by epidermal growth factor and tumor necrosis fac-
tor-α signaling pathways [22-24], but nothing is known about
what regulates its expression in subpopulations of cells in the
mammary anlage or TEBs.
Our original observation of an increased number of K6a-posi-
tive cells in the mature mammary glands from C/EBPβ-null
mice correlated with a block in development, suggesting an
accumulation of more primitive cells [6]. Several other groups
have also observed K6-positive cells in their mouse models of
mammary gland development, supporting the idea that K6 may
indeed be a putative marker of progenitor cells in the gland.
For example, Stingl and colleagues have recently described a
population of mouse mammary cells called 'colony-forming
cells' or Ma-CFCs that were isolated by fluorescence-acti-
vated cell sorting based on a CD24highCD49flow profile and
occurred with a frequency of about 1 in 63 cells [5]. Although
these cells did not display outgrowth potential in fat pad trans-
plantation experiments, Ma-CFCs were defined by Stingl and
colleagues as progenitor cells that are able to grow discrete
colonies on low-density adherent cultures. Both mRNA and
protein levels of K6 were enriched in these Ma-CFC cells,
which also had increased expression of other luminal cell
markers, such as K8, K18, and K19.
Figure 6
Progesterone receptor (PR)/bromodeoxyuridine expression and co- localization in keratin 6ab (K6ab)-null mammary glands Progesterone receptor (PR)/bromodeoxyuridine expression and co-
localization in keratin 6ab (K6ab)-null mammary glands. Mammary gland 
sections from wild-type (a) or K6ab-null (b) transplanted tissue after 10 
weeks of outgrowth were treated for 2 days with estrogen and proges-
terone and stained for PR (red) and BrdUrd (green) by indirect immun-
ofluorescence. The inset images show increased magnification of 
double-positive cells. White arrows indicate proliferating myoepithelial 
cells. Scale bar, 50 µm. (c) Cells positive for each marker, or those that 
co-localized (yellow arrowheads), were quantified and expressed as a 
percentage of total luminal epithelial cells. Error bars represent the 
SEM, and asterisks indicate statistical significance (p < 0.05).Available online http://breast-cancer-research.com/content/8/3/R29
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Notch signaling has been implicated in stem cell self-renewal
[25]. Recombination signal binding protein, J-type (RBP)-J is
the common transcriptional mediator of Notch receptors. Tar-
geted deletion of RBP-J in the mammary gland resulted in a
transient increase in K6 expression in luminal epithelial cells
during early pregnancy [26]. These results suggested an
arrest at an immature stage of mammary gland development,
similar to that in the C/EBPβ-null mice.
In addition to being a marker of early mammary gland develop-
ment and putative progenitor cells, K6 expression has been
observed in a subpopulation of cells in both mammary hyper-
plasias and tumors induced by transgenic expression of Wnt-
1, β-catenin, or Myc [7]. However, hyperplasias and tumors
induced by polyoma middle T antigen, Neu or H-Ras are more
homogeneous and do not express K6. Li and colleagues there-
fore suggested that some tumors might arise from the amplifi-
cation of progenitor cells, whereas the others might promote
differentiation of the progenitors, thereby depleting the
population.
Lisanti and colleagues have reported increased K6 expression
in the hyperplastic mammary ducts of caveolin-1-null mice,
along with increased β-catenin expression [27]. They pro-
posed that activation of the Wnt/β-catenin pathway led to the
accumulation of mammary progenitor cell accumulation.
Finally, overexpression of the proto-oncogene Met, a receptor
tyrosine kinase, under the control of the MSCV (mouse stem
cell virus), resulted in non-progressive mammary neoplasms
[28]. These lesions contained large numbers of K6-positive
cells, again suggesting that this might represent the expansion
of a progenitor cell population. However, when Met was over-
expressed under the control of MMTV (mouse mammary tumor
virus), no neoplasms were detected and K6 expression was
not observed.
Keratinocytes activated by injury or stress express K6 and
migrate to the site of wound healing [13]. Although K6 expres-
sion has been associated with hyperproliferation, expression
of K6 in the epidermis does not overlap with the incorporation
of [3H]thymidine [29], supporting our observation that K6-pos-
itive cells are mostly quiescent. Instead, it is possible that K6
regulates a migratory function required in progenitor cells so
as to permit their dispersal throughout the mammary gland.
However, deletion of K6a and K6b did not seem to have any
detectable effect on ductal elongation in mammary glands
from intact animals or in outgrowths from tissue transplants.
The lack of an overt mammary gland phenotype in the K6a/b
double knockout mice was not unexpected, because it has
been difficult to demonstrate the functional properties of most
markers used to isolate and characterize stem and progenitor
cells by means of gene deletion in genetically engineered
mice. For example, deletion of one of the best-characterized
mammary stem/progenitor cell markers, CD49f (α6-integrin),
did not have any reported mammary gland developmental phe-
notypes in transplants of the null mammary anlage [30]. This
unexpected result might be considered surprising, because
integrins have been suggested to have an essential function in
adhesion in the stem cell niche [31]. Furthermore, conditional
deletion of CD29 (β1-integrin) resulted in impaired alveolar
development and lactation [32], with no reported effect on
ductal morphogenesis [32]. Although the triple knockout
mouse for Brcp1 (Abcg2), Mdr1a, and Mdr1b resulted in the
loss of side population (SP) cells, a phenotype defined by the
ability of these cells to efflux Hoechst 33342 dye associated
with stem/progenitor cells, there was no mention of a mam-
mary gland development phenotype in these mice [33].
A key experiment to test the functional effect of loss of progen-
itor cell markers requires limiting dilution serial transplantation
to distinguish long-term versus short-term engraftment of
stem/progenitor cells deleted for specific genes. This has only
recently been accomplished for CD49f and CD29 [4]. It is
most likely that many of these markers may be only just mark-
ers, and may not have critical functions. However, notwith-
standing this caveat, it is crucial to identify lineage markers as
tools for the characterization of different mammary cell types.
K6 seems to be one such useful lineage marker.
In the present study, an increase in the number of proliferating
PR-positive cells was observed after the loss of K6a/b. K6a-
positive cells co-localized with steroid receptor expression,
but rarely with BrdU incorporation, a marker of proliferation.
Normally, steroid receptor expression does not overlap with
proliferation [19-21]. However, inappropriate co-localization of
steroid receptors with proliferative markers is often found in
pre-neoplastic disease [34-36]. A recent study suggests that
activated TGF-β acts in an autocrine manner to prevent ERα-
positive mammary epithelial cells from proliferating [37]. In
addition to an increased number of K6a-positive MECs, C/
EBPβ-null mice have increased levels of activated TGF-β as
well as increased expression of PR and decreased prolifera-
tion in the mature mammary gland, further supporting this
hypothesis [6,38]. Interestingly, ERα and PR have also been
proposed to be markers of mammary progenitor cells, repre-
senting a quiescent population scattered throughout the gland
hypothesized to self-renew through asymmetric division
[39,40]. Human mammary epithelial cells sorted for expres-
sion of p21 or Msi-1, suggested to be putative stem cell mark-
ers, also had enriched expression of steroid receptors.
Additionally, SP cells had sixfold enrichment of ERα-positive
cells in this model system; however, K6 expression was not
analyzed [40]. Alternatively, recent studies with a xenograft
model of T47D human breast cancer cells expressing ER plus
different PR isoforms demonstrated increased K6 mRNA
expression in tumors in response to treatment with E + P that
was dependent on the expression of PR [41]. Thus, the pre-
cise relationship between steroid receptor and K6 expression
in normal mammary epithelial cells, and how this might beBreast Cancer Research    Vol 8 No 3    Grimm et al.
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altered in breast cancer, remains to be established, but it is
interesting to speculate that K6 might have a function in this
interaction.
Conclusion
Although K6a may not be essential for mammary gland devel-
opment, the loss of both K6a and K6b resulted in an increased
number of PR-positive MECs and decreased proliferation after
exposure to steroid hormones. There was also increased co-
localization of PR and BrdU, suggesting alterations in pattern-
ing events important for lobuloalveolar development. Although
K6 does not seem to have a function in progenitor cells, it may
still provide a useful lineage marker for studies of mammary
gland development and tumorigenesis.
Note added in proof
Interestingly, an unexpected function for keratin 17, a potential
keratin 6 partner, in regulating protein synthesis and epithelial
cell growth has been reported recently [42].
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